Trevi Therapeutics (TRVI) Competitors $7.33 -0.08 (-1.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.40 +0.07 (+0.94%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. HCM, IMVT, KYMR, CRNX, MOR, ALVO, RXRX, MIRM, CPRX, and NAMSShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include HUTCHMED (HCM), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Its Competitors HUTCHMED Immunovant Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Recursion Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals NewAmsterdam Pharma Trevi Therapeutics (NASDAQ:TRVI) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Which has more risk & volatility, TRVI or HCM? Trevi Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Do insiders & institutionals hold more shares of TRVI or HCM? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer TRVI or HCM? In the previous week, Trevi Therapeutics had 3 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for Trevi Therapeutics and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.91 beat Trevi Therapeutics' score of 0.16 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TRVI or HCM? Trevi Therapeutics presently has a consensus price target of $20.88, suggesting a potential upside of 184.79%. HUTCHMED has a consensus price target of $28.00, suggesting a potential upside of 62.13%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is TRVI or HCM more profitable? HUTCHMED's return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -58.41% -52.52% HUTCHMED N/A N/A N/A Which has preferable valuation & earnings, TRVI or HCM? HUTCHMED has higher revenue and earnings than Trevi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.45-16.29HUTCHMED$630.20M4.78$37.73MN/AN/A SummaryTrevi Therapeutics beats HUTCHMED on 8 of the 13 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$868.55M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-16.2917.6228.6723.80Price / SalesN/A179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book5.648.508.275.55Net Income-$47.91M-$55.06M$3.24B$259.03M7 Day Performance-6.86%-3.98%-3.69%-4.59%1 Month Performance22.58%9.59%4.33%4.46%1 Year Performance154.51%6.72%25.95%18.03% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics2.4543 of 5 stars$7.33-1.1%$20.88+184.8%+136.5%$868.55MN/A-16.2920News CoveragePositive NewsUpcoming EarningsShort Interest ↑HCMHUTCHMED3.2074 of 5 stars$17.74+0.9%$19.00+7.1%-6.5%$3.07B$630.20M0.001,811Upcoming EarningsIMVTImmunovant1.4495 of 5 stars$17.70-1.2%$36.30+105.1%-45.6%$3.06BN/A0.00120Upcoming EarningsKYMRKymera Therapeutics3.5763 of 5 stars$45.14-2.3%$59.11+31.0%-3.4%$2.94B$47.07M-14.56170News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.3269 of 5 stars$30.95-0.5%$69.50+124.6%-46.5%$2.91B$1.04M0.00210News CoveragePositive NewsUpcoming EarningsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech3.3884 of 5 stars$8.64+0.1%$16.00+85.2%-24.0%$2.60B$491.98M14.881,032Positive NewsRXRXRecursion Pharmaceuticals1.5365 of 5 stars$6.40+9.6%$7.00+9.4%-22.6%$2.60B$58.84M-3.62400Upcoming EarningsGap DownHigh Trading VolumeMIRMMirum Pharmaceuticals3.7376 of 5 stars$51.95+0.0%$65.50+26.1%+29.6%$2.57B$336.89M-32.27140News CoveragePositive NewsUpcoming EarningsCPRXCatalyst Pharmaceuticals4.8982 of 5 stars$21.01-0.1%$32.83+56.3%+24.7%$2.57B$491.73M13.3880Positive NewsUpcoming EarningsNAMSNewAmsterdam Pharma3.2139 of 5 stars$22.56+1.6%$41.30+83.1%+23.4%$2.53B$45.56M-12.004Positive NewsUpcoming Earnings Related Companies and Tools Related Companies HCM Alternatives IMVT Alternatives KYMR Alternatives CRNX Alternatives MOR Alternatives ALVO Alternatives RXRX Alternatives MIRM Alternatives CPRX Alternatives NAMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts